Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflecte

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed

Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strateg

SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”

Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large growth in s

Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall respon

Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall respon

Adagene is essentially a single-asset bet on ADG126, which is a masked anti-CTLA-4 antibody designed

SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: AD

Guggenheim analyst Paul Jeng maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price targ

Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) ar

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirm

SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Comp

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and

Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confir

Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.24) per share which missed the analyst consen

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC

Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the target of a significant growth i

SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Compan

Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large drop in sho

SAN DIEGO and SUZHOU, China, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company

Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) saw a significant growth in short intere

Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients

Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients

Shares of Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) have been assigned an average

Guggenheim analyst Paul Jeng initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and an

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Adagene (NASDAQ:ADAG) with a

HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and lowers t

Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.19) per share which beat the analyst consensu

Leerink Partners analyst Daina Graybosch initiates coverage on Adagene (NASDAQ:ADAG) with a Outpe

Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery

HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintai

- Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoi

HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and raises t

HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintai

Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver an

Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development

HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintai

HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintai